ada standards of care 2025 glp-1 receptor agonists recommendations Indications for GLP-1/GIP RA Summary Sheet and Beyond! 2025 ADA Standards of Medical

AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi and Hypera S.A

Tirzepatide was more efficacious in reducing body weight

The Revolutionary Role of GLP-1 Agonists and SGLT-2 Inhibitors in Managing Diabetes and Chronic Kidney Disease Shankar Chakkera, Elizabeth J

Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator, while all tirzepatide doses were safe in terms of serious adverse events and mortality

GLP-1 RAs are used for managing blood glucose levels in people with type 2 diabetes mellitus and have also been licensed for use in weight loss treatment

Diabetic kidney disease, a common complication in patients with type 2 diabetes mellitus, is